Trial Profile

A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP Study)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2024 Number of treatment arms are decreased from 2 to 1 by the removal of Metastatic cohort arm.
18 Apr 2024 Status changed from recruiting to completed.
09 Mar 2023 According to Telix Pharmaceuticals media release, company announced presentation from this trial in session ''Clinical Trials in Progress'' to report on the potential utility of TLX250-CDx in urothelial carcinoma or bladder cancer , at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan 12-Mar-2023, 10:45 AM-12:15 PM.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com